Holen Sie sich die Stockscreener-App
4.23
0.36%
-0.0153
Schlusskurs vom Vortag:
$4.2453
Offen:
$4.22
24-Stunden-Volumen:
3,052
Relative Volume:
0.06
Marktkapitalisierung:
$5.63M
Einnahmen:
$61,000
Nettoeinkommen (Verlust:
$-5.46M
KGV:
-0.6468
EPS:
-6.54
Netto-Cashflow:
$-6.76M
1W Leistung:
+6.82%
1M Leistung:
+7.91%
6M Leistung:
+6.55%
1J Leistung:
-28.43%
1-Tages-Spanne:
$4.15
$4.23
1-Wochen-Bereich:
$3.575
$4.45
52-Wochen-Spanne:
$3.03
$6.43
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Firmenname
Titan Pharmaceuticals Inc De
Sektor
Branche
Telefon
(650) 244-4990
Adresse
400 OYSTER POINT BLVD, SAN FRANCISCO
Vergleichen Sie TTNP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
4.23 | 5.65M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-06-26 | Eingeleitet | Maxim Group | Buy |
| 2017-11-10 | Herabstufung | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Aktie (TTNP) Neueste Nachrichten
Major Pharma Merger Advances: Semnur Pharmaceuticals-Denali Capital Deal Gets Shareholder Green Light - Stock Titan
Biotech Acurx Pharmaceuticals Secures Future on Nasdaq by Meeting Critical $1 Bid, $2.5M Equity Rules - Stock Titan
Is Titan Pharmaceuticals Inc. trending in predictive chart models2025 Biggest Moves & Verified Entry Point Signals - Newser
Using Python tools to backtest Titan Pharmaceuticals Inc. strategiesJuly 2025 Short Interest & Weekly Top Performers Watchlists - Newser
$30M Stock Offering: Cognition Therapeutics Advances Phase 3 Programs for Neurodegenerative Drug - Stock Titan
$15 Million IPO: Inflammatory Disease Biotech Curanex Launches on Nasdaq with Botanical Drug Focus - Stock Titan
Titan Pharmaceuticals Stock Surges 23% After Hours on Stockholder Approval of Three-Way Merger - Benzinga
$15 Million IPO: Botanical Drug Developer Curanex Lists on Nasdaq to Advance Ulcerative Colitis Treatment - Stock Titan
Sector ETF performance correlation with Titan Pharmaceuticals Inc.2025 Price Targets & AI Optimized Trading Strategy Guides - Newser
Will a bounce in CEMEX S.A.B. de C.V. Depositary Receipt offer an exitJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - Newser
13M Patient Market: NRx Pharmaceuticals Secures Major FDA Fast Track Win for Revolutionary Depression Drug - Stock Titan
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Up 304.7% in July - Defense World
Elite Pharmaceuticals Revenue More Than Doubles as New ADHD Drug Launch Drives Record Growth - Stock Titan
How Titan Pharmaceuticals Inc. stock performs during market volatilityMarket Growth Summary & Expert Curated Trade Ideas - Newser
Sonoma's First Major Consumer Product Hits Walmart Shelves: New Tech-Based Diaper Rash Treatment - Stock Titan
Ketamir-2 outperforms ketamine, plans Phase 2a FDA submission in Q4 2025 - Stock Titan
X4 Pharmaceuticals Overhauls Leadership: $60M Deal Brings CTI BioPharma's $1.7B Exit Team Onboard - Stock Titan
CVKD Files 8-K; Exhibit 99.1 Contains Q2 2025 Financials - Stock Titan
FDA Fast Track Breakthrough: NRX-100 Shows 63% Success Rate in Suicidal Depression Treatment - Stock Titan
Will earnings trigger a reversal in Titan Pharmaceuticals Inc.Daily Swing Candidate Analysis with Chart Patterns - Newser
Best Pharmaceutical Stocks to Buy in 2025 - The Motley Fool
Elite Pharmaceuticals Earnings Call: Key Corporate Updates and Q1 2026 Results Coming August 15 - Stock Titan
NRx Secures Florida Approval to Acquire Veterans Mental Health Provider Dura Medical - Stock Titan
Kiora's Q2 Earnings Reveal Dual Phase 2 Trials Progress and $110M Asia Partnership Opportunity - Stock Titan
PLBY regains Nasdaq compliance with new independent director appointment | PCSA SEC FilingForm 8-K - Stock Titan
Biotech Pioneer Processa Pharmaceuticals Embraces Crypto: Strategic Investment Meets Blockchain Innovation - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
RIGL files S-8 to register 825,000 shares for employee equity plans | RIGL SEC FilingForm S-8 - Stock Titan
TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc.TTNP - FinancialContent
Cumberland Pharmaceuticals Hits 23% Revenue Growth as DMD Drug Shows Major Heart Benefits - Stock Titan
Nuvectis Reports Clinical Trial Success: NXP900 Cancer Drug Advances as Cash Position Strengthens to $39M - Stock Titan
Biotech Terns Pharmaceuticals Appoints Chief People Officer, Awards Massive 500,000 Share Option Package - Stock Titan
Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan
Pharmaceutical Pioneer Artelo Makes History: Raises $9.5M to Build First-Ever Solana Treasury Strategy - Stock Titan
Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan
SHEN files 8-K, releases Q2 2025 earnings press release | ADIL SEC FilingForm 424B5 - Stock Titan
Acurx Pharmaceuticals Plans Major 1:20 Reverse SplitKey Details for Nasdaq Compliance - Stock Titan
Lexicon Pharmaceuticals Meets $1 Minimum Share Price, Secures Critical Nasdaq Listing Status - Stock Titan
Cumberland Pharmaceuticals Sets Q2 Earnings Date: FDA-Approved Drug Portfolio Update Coming August 5 - Stock Titan
NRx Pharmaceuticals Teams with Yale Expert to Reveal Latest CNS Treatment Innovations at BTIG Conference - Stock Titan
CG Oncology Secures Major Legal Victory: Court Rules No 5% Royalties on Promising Bladder Cancer Drug - Stock Titan
INM files 8-K on upcoming INM-901 Alzheimer’s data at AAIC 2025 | INM SEC FilingForm 8-K - Stock Titan
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
What are the latest earnings results for Titan Pharmaceuticals Inc.Achieve explosive financial results today - Jammu Links News
Phio Pharmaceuticals Advances Cancer Drug Production with Strategic US Manufacturing Partnership - Stock Titan
Mersana's 1:25 Reverse Split Aims to Save Nasdaq Listing: Key Details for Investors - Stock Titan
Lexicon Pharmaceuticals Schedules Pre-Market Q2 Earnings Release, 8:30 AM ET Conference Call - Stock Titan
CNS Pharmaceuticals CEO Shares Brain Cancer Treatment Vision at Investor Conference | CNSP Stock News - Stock Titan
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
Tonix Tackles 15-Year Fibromyalgia Treatment Void with Groundbreaking Patient Support Campaign - Stock Titan
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire
Finanzdaten der Titan Pharmaceuticals Inc De-Aktie (TTNP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):